


Rewritten paragraphs appear in the preceding "IN THE SPECIFICATION" section. Attached hereto is a marked-up version of the changes made to the specification paragraphs by the instant amendment. The attached pages are captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE" and are only included for the Examiner's convenience. Should any discrepancies be discovered, the version presented in the preceding "IN THE SPECIFICATION" section shall take precedence.

The content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter.

Applicants do not believe that any fee is due with this submission. However, please charge any fees associated with this filing or credit any overpayment to Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Applicants enclose a copy of the Notification of Missing Requirements.

Respectfully submitted,

  
Ronald B. Hildreth  
PTO Reg. No. 19,498

Rochelle K. Seide  
PTO Reg. No. 32,300  
Attorneys for Applicant

BAKER BOTTS, L.L.P.  
30 Rockefeller Plaza  
New York, NY 10112  
(212) 408-2626

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The paragraph beginning at page 7, line 8, and ending at page 7, line 13 has been amended as follows:

In one embodiment, the polynucleotide of the invention is 544 bp in full length whose detailed sequence is shown in SEQ ID NO: 3 with the ORF located at positions 81-521. Said polynucleotide was obtained as follows: human brain gt 11 cDNA library (Clontech) was used as a template and PCR was carried out with the synthetic forward primer A1 5'-AGAGTGGTGGTGGCTCCACTCTG-3' (SEQ ID NO. 1) and reverse primer B :5'-TGCTGTGCATGGTTCCGTCCATC-3' (SEQ ID NO. 2). A target fragment of 544bp was obtained. The sequencing of the PCR product gave the full length cDNA sequence shown in SEQ ID NO: 3.

The paragraph beginning at page 7, line 8, and ending at page 7, line 13 has been amended as follows:

Fig. 1 shows an alignment comparison of amino acid sequences of human LYC3 and other lysozymes. Fig. 1A shows a homology comparison of amino acid sequences of human LYC3 (SEQ ID NO. 4) and lysozyme C of *Trachypithecus francoisi* (gi|1790947)(SEQ ID NO. 11). Fig. 1B shows a homology comparison of amino acid sequences of human LYC3 (SEQ ID NO. 4) and lysozyme C of ring-necked pheasant (sp|p00702)(SEQ ID NO. 12). The identical amino acids are indicated by ":"

between the sequences, and the similar amino acids indicated by ". ". The similar amino acids are as follows: A,S,T; D,E; N,Q; R,K; I,L,M,V; F,Y,W.

The paragraph beginning at page 8, line 14, and ending at page 8, line 20 has been amended as follows:

In particular, in amino acid sequence of LYC3, there exists a 19 amino acids signature sequence of lysozyme and alpha-lactoalbumin: **CX<sub>3</sub>CX<sub>2</sub>(L/M/F)X<sub>3</sub>(D/E/N)(L/I)X<sub>5</sub>C** (SEQ ID NO. 10) [Note: In the sequence, X represents any amino acid, digits such as "2" denote the number of amino acid, "(L/M/H)" represents any of these three amino acids]. Lysozyme and alpha-lactoalbumin are two proteins related closely in evolution (Eur. J. Biochem. 182: 111-118). In the protein of the present invention, the sequence matching the signature is: CRMYCSDLLNPNLKDTVIC (residues 93-111 in SEQ ID NO: 4). It indicates that the LYC3 of the present invention belongs to lysozyme family, and has the relative functions of the lysozyme family.